+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
TauRx Pharmaceuticals Ltd - logo

TauRx Pharmaceuticals Ltd. discovers and develops treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. The company's best known product, LMTX, inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. The LMTX Phase 3 clinical trial programme, conducted in over 20 countries and involving over 1,900 patients, has recently completed. TauRx Pharmaceuticals Ltd. was founded in 2002 and is based in Singapore with a research facility in Aberdeen, Scotland.

From
From
From
Alzheimer s: Epidemiology Overview and Insights - Product Thumbnail Image

Alzheimer s: Epidemiology Overview and Insights

  • Report
  • April 2018
  • 50 Pages
From
Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Product Thumbnail Image

Alzheimer's Disease Global Clinical Trials Review, H2, 2019

  • Clinical Trials
  • December 2019
  • 1222 Pages
From
From
Alzheimer's Disease - Pipeline Review, H1 2020 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 1716 Pages
From
From
Tau Inhibitor -Pipeline Insight, 2019 - Product Thumbnail Image

Tau Inhibitor -Pipeline Insight, 2019

  • Drug Pipelines
  • January 2019
  • 60 Pages
From
Alzheimer's Disease: Dynamic Market Forecast to 2026 - Product Thumbnail Image

Alzheimer's Disease: Dynamic Market Forecast to 2026

  • Report
  • October 2018
  • 52 Pages
From
From
Aphasia Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Aphasia Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • October 2018
  • 51 Pages
From
Loading Indicator
adroll